Richard Seabrook
Member
BOD
GHIT
Japan
Biography
Richard previously led the Business Development Team at Wellcome which, in addition to undertaking substantive transactions and IP prosecution, managed £750M of product development translational funding put to work with industry, SMEs, not for profits and universities. Key outcomes include the discovery of KAE609, Plazomicin, Ridinilazole and Xanamem, multiple phase 2 studies in progress and discovery and commercialisation of the molecular diagnostic platform SAMBA . He was a Non-Executive Director for Wellcome Trust Trading Ltd and Wellcome International Ltd, board Observer for the Wellcome Trust Sanger Institute parent company. Currently Richard runs his own advisory business, 360Biomedical Ltd, undertaking due diligence, business and corporate development for both the private and public sectors.
Research Interest
Business management, Medicine science
